Compare Biocon with Orchid Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ORCHID PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ORCHID PHARMA 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ORCHID PHARMA BIOCON /
ORCHID PHARMA
 
P/E (TTM) x 31.9 -120.5 - View Chart
P/BV x 3.8 34.6 11.0% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 BIOCON    ORCHID PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
ORCHID PHARMA
Sep-13
BIOCON /
ORCHID PHARMA
5-Yr Chart
Click to enlarge
High Rs707194 364.6%   
Low Rs55435 1,582.3%   
Sales per share (Unadj.) Rs91.9276.5 33.2%  
Earnings per share (Unadj.) Rs16.7-79.2 -21.1%  
Cash flow per share (Unadj.) Rs24.2-43.5 -55.6%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs101.653.9 188.4%  
Shares outstanding (eoy) m600.0070.45 851.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.90.4 1,656.6%   
Avg P/E ratio x37.7-1.4 -2,610.4%  
P/CF ratio (eoy) x26.1-2.6 -989.9%  
Price / Book Value ratio x6.22.1 292.3%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m378,3308,067 4,690.1%   
No. of employees `0006.12.8 219.0%   
Total wages/salary Rs m11,6532,527 461.1%   
Avg. sales/employee Rs Th8,994.36,956.1 129.3%   
Avg. wages/employee Rs Th1,900.7902.5 210.6%   
Avg. net profit/employee Rs Th1,635.3-1,993.0 -82.1%   
INCOME DATA
Net Sales Rs m55,14419,477 283.1%  
Other income Rs m1,444407 354.6%   
Total revenues Rs m56,58819,884 284.6%   
Gross profit Rs m15,8831,103 1,440.5%  
Depreciation Rs m4,4782,519 177.8%   
Interest Rs m7095,227 13.6%   
Profit before tax Rs m12,140-6,236 -194.7%   
Minority Interest Rs m920 45.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m2,123-125 -1,695.7%   
Profit after tax Rs m10,026-5,580 -179.7%  
Gross profit margin %28.85.7 508.8%  
Effective tax rate %17.52.0 871.1%   
Net profit margin %18.2-28.7 -63.5%  
BALANCE SHEET DATA
Current assets Rs m48,22811,014 437.9%   
Current liabilities Rs m30,37632,060 94.7%   
Net working cap to sales %32.4-108.1 -30.0%  
Current ratio x1.60.3 462.2%  
Inventory Days Days6895 72.0%  
Debtors Days Days8634 254.8%  
Net fixed assets Rs m64,13029,440 217.8%   
Share capital Rs m3,000705 425.8%   
"Free" reserves Rs m57,9802,043 2,838.5%   
Net worth Rs m60,9803,800 1,604.8%   
Long term debt Rs m15,7669,018 174.8%   
Total assets Rs m121,92446,510 262.1%  
Interest coverage x18.1-0.2 -9,384.2%   
Debt to equity ratio x0.32.4 10.9%  
Sales to assets ratio x0.50.4 108.0%   
Return on assets %8.8-0.8 -1,158.4%  
Return on equity %16.4-146.9 -11.2%  
Return on capital %16.8-3.7 -448.6%  
Exports to sales %28.137.9 74.2%   
Imports to sales %18.922.6 83.4%   
Exports (fob) Rs m15,5067,378 210.2%   
Imports (cif) Rs m10,3994,406 236.0%   
Fx inflow Rs m15,5067,513 206.4%   
Fx outflow Rs m10,3995,649 184.1%   
Net fx Rs m5,1071,865 273.9%   
CASH FLOW
From Operations Rs m11,5461,682 686.6%  
From Investments Rs m-7,138-9,860 72.4%  
From Financial Activity Rs m-2,4176,644 -36.4%  
Net Cashflow Rs m2,103-1,535 -137.0%  

Share Holding

Indian Promoters % 40.4 32.3 125.1%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 4.6 182.6%  
FIIs % 10.7 3.3 324.2%  
ADR/GDR % 0.0 4.6 -  
Free float % 19.9 55.3 36.0%  
Shareholders   109,995 84,811 129.7%  
Pledged promoter(s) holding % 0.0 54.9 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   GSK PHARMA  JUBILANT PHARMOVA   DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Dips 300 Points, Nifty Falls Below 14,800; Godrej Consumer Zooms 10%(09:30 am)

Asian share markets fell for a second straight session today to one-month lows as investors speculated surging commodity prices.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 12, 2021 10:53 AM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS